Australia's largest stock trading and investment forum Australia's #1 stock forum

MSB

2.10%

$1.17 mesoblast limited

MSB to dispute FDA finding in Type A meeting, page-591

First 591 Last

Share
Profile

Follow
ddwn

12,398 Posts.

3370

09/10/20

17:37

Post #: 47984926
Share

Originally posted by stockrock: ↑

In revisiting some announcements in 2018... I found something quite informative.

On the 22nd Feb 2018 MSB announced that they had met the primary endpoint for the phase 3 SR-aGVHD clinical trial. At that time they said this

”Based on interactions with the FDA, Mesoblast believes successful results from the completed phase 3 trial, together with Day 180 safety and quality of life parameters in these patients, may provide sufficient clinical evidence for filing for accelerated approval...”

This was reiterated in June 2018 when the 100 day survival data was strong and was to be presented at a conference.

Then on 20 Sep 2018, the 180 safety data was available and continued to show strong survival outcomes. At this point it appears management made a decision to go for full approval with priority review.

I can’t access the webcasts around that time, but that is when I recall Silviu being asked why they had not taken the accelerated approval pathway and he responded that they were very confident with full approval given the strength of the data in hand.

If someone has luck accessing that webcast, it would be good to have the accuracy of my recollection confirmed or clarified.

In any case, it appears the FDA and MSB has prior discussions on accelerated approval and the FDA may have even encouraged them to take that path... I say this because it sounds like the discussions were positive... but instead it appears management went for full approval instead.

This could partly explain the combative language/attitude the FDA conveyed in their briefing notes. Maybe a little annoyed MSB tried to overreach for full approval... when an accelerated pathway was available and they suggested MSB would be in a position to apply for such an expedited approval pathway.

This does alleviate some of my concern when it comes to the eligibility for accelerated approval, in that the data needs to be “adequate and well controlled” as well as the use of 28 ORR as surrogate data. It appears MSB already have guidance from the FDA on all of this.

What MSB have now is a successful phase 3 single arm trial, strong 180 day survival data... and a 9-1 ODAC vote. The ODAC vote probably puts it well beyond doubt that the data is considered “adequate and well controlled”.

Expand

Thanks @stockrock - that's a great find.

We don't know what was discussed behind closed doors, but this scenario makes sense.

I've put the blame on the FDA, but it may be that SI & management thought they'll give a full approval path a try first and then the Accelerated Approval as a fallback.

If that's the case, I hope that the FDA look at the broader picture and judge on the unmet medical need rather than punish Mesoblast for going down a different path than the FDA have suggested

Bring on the Type A request & meeting - let's just get on with it and get GVHD approved!

MSB Price at posting: $3.37 Sentiment: Buy Disclosure: Held
16 Upvote

0 Great analysis

Reply

Top Stories

ARN

Aldoro shares jump 47% on news of strong niobium recoveries from Namibia play

Week 28 Wrap: ASX hits all time high; CBA shares' two realities; US inflation hits 3% ahead of China plenum

RCE

Recce scores US$2M deal from US Department of Defense for burn wound infections gel

Shekel Brainweigh and Calmer Co lead innovations in the retail space

I88

Infini soars 50% as company reveals it could’ve just made uranium history – redefining what it means to be “high grade”

There are more pages in this discussion • 427 more messages in this thread...

First 591 Last

Add MSB (ASX) to my watchlist

(20min delay)
Last $1.17		Change -0.025(2.10%)		Mkt cap ! $1.330B

Open	High	Low	Value	Volume
$1.18	$1.22	$1.15	$6.344M	5.404M

Buyers (Bids)

No.	Vol.	Price($)
1	8683	$1.16

Sellers (Offers)

Price($)	Vol.	No.
$1.17	32999	1

View Market Depth

No.	Vol.	Price($)
1	8683	1.155
7	295447	1.150
3	70786	1.145
6	196386	1.140
3	75486	1.135

Price($)	Vol.	No.
1.165	32999	1
1.170	62618	6
1.175	48590	3
1.180	79079	4
1.185	17090	2

Last trade - 16.10pm 15/07/2024 (20 minute delay)

MSB (ASX) Chart

MSB to dispute FDA finding in Type A meeting, page-591

Aldoro shares jump 47% on news of strong niobium recoveries from Namibia play

Week 28 Wrap: ASX hits all time high; CBA shares' two realities; US inflation hits 3% ahead of China plenum

Recce scores US$2M deal from US Department of Defense for burn wound infections gel

Shekel Brainweigh and Calmer Co lead innovations in the retail space

Infini soars 50% as company reveals it could’ve just made uranium history – redefining what it means to be “high grade”

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News

MSB to dispute FDA finding in Type A meeting, page-591

Top Stories

Aldoro shares jump 47% on news of strong niobium recoveries from Namibia play

Week 28 Wrap: ASX hits all time high; CBA shares' two realities; US inflation hits 3% ahead of China plenum

Recce scores US$2M deal from US Department of Defense for burn wound infections gel

Shekel Brainweigh and Calmer Co lead innovations in the retail space

Infini soars 50% as company reveals it could’ve just made uranium history – redefining what it means to be “high grade”

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News